ProBioGen AG ads

🔬 Manufacturing White Paper: Integrating Manufacturing Strategy Early for Biologics Success From clone selection through scale-up and tech transfer, biologics development is shaped by a series of interconnected decisions that ultimately impact the manufacturability of a molecule. Each decision influences the next, making it important to consider manufacturing requirements from the earliest stages of development. When cell line development and manufacturing are approached as connected workflows rather than sequential handoffs, development becomes more efficient, tech transfer is smoother, and manufacturing readiness is strengthened from the earliest stages. Developed in collaboration with Fierce Biotech, #ProBioGen's latest white paper explores how integrating manufacturing considerations early helps build robust, scalable CMC strategies. 📥 Access the white paper and read more. #Biologics #CMC #Biomanufacturing #CDMO

Meet Us at CPHI Milan! We're heading to Milan this October and looking forward to the conversations ahead with partners and peers across the biopharma industry. Representing ProBioGen on-site: Michiel Stork, PhD, VP Business Development, and Charlotte Coenders, Business Development Manager. Reach out to Michiel and Charlotte to find a time to connect. 📆 October 6–8 📍 Milan, Italy #CPHI #CPHIMilan

Get the latest jobs and industry news

What speaks loudest about a CDMO's approach to partnership? Ask the clients. With over 70% returning for subsequent programs, the answer is consistent: clarity when it matters, communication that holds up under pressure, and a team that stays invested beyond the first delivery. 💡 Explore what makes strong CDMO partnerships in our latest blog. Link in the comments.

Your reputation rides on every LVV decision, and “trust me” doesn’t cut it with your CMC and QA peers. Lenti.RiGHT gives you a documented, GMP-grade HEK293-based platform with inducible expression and single-event genomic integration of all vector components, so you can point to hard data instead of hopeful anecdotes. From pool to clone, you get stable, predictable production performance—and a single, accountable partner for development and GMP manufacturing—so you can stand in front of any team and say, “Yes, the platform can handle it.”

You’re under pressure to hit aggressive milestones without compromising quality. Lenti.RiGHT gives you a GMP-grade HEK293-based platform with inducible expression and single-event genomic integration of all vector components. That means stable, predictable production performance from pool to clone, fewer surprises in scale-up, and a single partner managing development and GMP manufacturing end to end.